Product Name :
Ulixertinib hydrochloride
Description:
Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line.
CAS:
1956366-10-1
Molecular Weight:
469.79
Formula:
C21H23Cl3N4O2
Chemical Name:
4-5-chloro-2-[(propan-2-yl)amino]pyridin-4-yl-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide; chlorohydrogen
Smiles :
Cl.CC(C)NC1C=C(C(Cl)=CN=1)C1=CNC(=C1)C(=O)N[C@H](CO)C1=CC=CC(Cl)=C1
InChiKey:
DKGYQCPFBWFTHM-FSRHSHDFSA-N
InChi :
InChI=1S/C21H22Cl2N4O2.ClH/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13;/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29);1H/t19-;/m1./s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of Product information|CAS Number: 1956366-10-1|Molecular Weight: 469.79|Formula: C21H23Cl3N4O2|Chemical Name: 4-5-chloro-2-[(propan-2-yl)amino]pyridin-4-yl-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide; chlorohydrogen|Smiles: Cl.BT424 supplier CC(C)NC1C=C(C(Cl)=CN=1)C1=CNC(=C1)C(=O)N[C@H](CO)C1=CC=CC(Cl)=C1|InChiKey: DKGYQCPFBWFTHM-FSRHSHDFSA-N|InChi: InChI=1S/C21H22Cl2N4O2.Cidofovir Autophagy ClH/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13;/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29);1H/t19-;/m1.PMID:33349219 /s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 125 mg/mL (266.08 mM; Need ultrasonic). H2O : 0.1 mg/mL (0.21 mM; ultrasonic and warming and heat to 80°C).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Combined Ulixertinib (BVD-523; 10, 20, 30 μM; 48 hours) and VS-5584 treatment causes significant induction of cell death in human pancreatic cancer (HPAC) cells in PDAC cell lines BxPC-3, MIAPaCa-2, and CFPAC-1.|Products are for research use only. Not for human use.|
